GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

2nd Annual Gene Therapy for ophthalmic Disorders, digital event

UK MHRA grants GenSight Biologics’ LUMEVOQ® ophthalmic gene therapy Promising Innovative Medicine designation

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics on Track to Submit LUMEVOQ® for European Approval in September 2020 Following Pre-Submission Meeting with EMA

GenSight Biologics Provides Update on Operations in the Context of COVID-19